TRADES
Latest Trades
2880
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 14 Jan 2022 Buy NVTA INVITAE CORP 102,644 0.0271
ARKG 14 Jan 2022 Sell EVGN EVOGENE LTD 4,700 0.0002
ARKG 14 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 3,300 0.0007
ARKG 14 Jan 2022 Sell AQB AQUABOUNTY TECHNOLOGIES INC 324,239 0.0141
ARKG 13 Jan 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 38,821 0.1985
ARKG 13 Jan 2022 Buy TDOC TELADOC HEALTH INC 13,400 0.0243
ARKG 13 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 36,800 0.0117
ARKG 13 Jan 2022 Buy QSI QUANTUM-SI INC 30,121 0.0039
ARKG 13 Jan 2022 Buy NVTA INVITAE CORP 23,700 0.0063
ARKG 13 Jan 2022 Sell EVGN EVOGENE LTD 2,900 0.0001
ARKG 13 Jan 2022 Sell AQB AQUABOUNTY TECHNOLOGIES INC 14,575 0.0006
ARKG 12 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 7,780 0.0027
ARKG 12 Jan 2022 Buy QSI QUANTUM-SI INC 9,680 0.0013
ARKG 12 Jan 2022 Buy PSNL PERSONALIS INC 3,691 0.0010
ARKG 12 Jan 2022 Buy ONEM 1LIFE HEALTHCARE INC 150,000 0.0471
ARKG 12 Jan 2022 Buy EXAS EXACT SCIENCES CORP 41,103 0.0724
ARKG 12 Jan 2022 Sell EVGN EVOGENE LTD 10,883 0.0004
ARKG 12 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 242,472 0.0360
ARKG 12 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 2,160 0.0004
ARKG 12 Jan 2022 Sell AQB AQUABOUNTY TECHNOLOGIES INC 225,619 0.0097
ARKG 11 Jan 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 19,000 0.0060
ARKG 11 Jan 2022 Buy EXAS EXACT SCIENCES CORP 300 0.0005
ARKG 11 Jan 2022 Sell EVGN EVOGENE LTD 53,559 0.0020
ARKG 11 Jan 2022 Sell AQB AQUABOUNTY TECHNOLOGIES INC 926,500 0.0409
ARKG 10 Jan 2022 Buy TDOC TELADOC HEALTH INC 31,800 0.0553
ARKG 10 Jan 2022 Buy QSI QUANTUM-SI INC 9,614 0.0012
ARKG 10 Jan 2022 Buy NVTA INVITAE CORP 21,900 0.0057
ARKG 10 Jan 2022 Buy NRIX NURIX THERAPEUTICS INC 61,324 0.0326
ARKG 10 Jan 2022 Sell IONS IONIS PHARMACEUTICALS INC 326,031 0.2190
ARKG 10 Jan 2022 Buy EXAS EXACT SCIENCES CORP 49,498 0.0785
ARKG 10 Jan 2022 Sell EVGN EVOGENE LTD 27,599 0.0009
ARKG 10 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 50,000 0.0069
ARKG 10 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 54,800 0.0109
ARKG 10 Jan 2022 Sell AQB AQUABOUNTY TECHNOLOGIES INC 280,755 0.0120
ARKG 7 Jan 2022 Buy VCYT VERACYTE INC 11,700 0.0087
ARKG 7 Jan 2022 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 571,269 0.1693
ARKG 7 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 63,400 0.0218
ARKG 7 Jan 2022 Buy QSI QUANTUM-SI INC 94,738 0.0132
ARKG 7 Jan 2022 Buy NRIX NURIX THERAPEUTICS INC 178,585 0.1070
ARKG 7 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 31,621 0.0063
ARKG 7 Jan 2022 Buy BLI BERKELEY LIGHTS INC 108,000 0.0226
ARKG 6 Jan 2022 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 841,100 0.2414
ARKG 6 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 28,000 0.0095
ARKG 6 Jan 2022 Buy QSI QUANTUM-SI INC 101,895 0.0140
ARKG 6 Jan 2022 Buy PSNL PERSONALIS INC 59,000 0.0150
ARKG 6 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 25,739 0.0548
ARKG 6 Jan 2022 Buy NRIX NURIX THERAPEUTICS INC 44,628 0.0259
ARKG 6 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 698,931 0.1008
ARKG 6 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 4,000 0.0008
ARKG 5 Jan 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 43,264 0.1907
ARKG 5 Jan 2022 Buy TDOC TELADOC HEALTH INC 17,000 0.0290
ARKG 5 Jan 2022 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 983,695 0.2668
ARKG 5 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 299,800 0.1005
ARKG 5 Jan 2022 Buy PSNL PERSONALIS INC 118,000 0.0306
ARKG 5 Jan 2022 Buy ONEM 1LIFE HEALTHCARE INC 378,416 0.1324
ARKG 5 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 46,059 0.1006
ARKG 5 Jan 2022 Buy NRIX NURIX THERAPEUTICS INC 79,249 0.0436
ARKG 5 Jan 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 347,835 0.0487
ARKG 5 Jan 2022 Buy CRSP CRISPR THERAPEUTICS AG 9,800 0.0137
ARKG 5 Jan 2022 Buy CGEN COMPUGEN LTD 71,500 0.0061
ARKG 5 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 18,600 0.0263
ARKG 4 Jan 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 32,919 0.1398
ARKG 4 Jan 2022 Buy VCYT VERACYTE INC 69,015 0.0505
ARKG 4 Jan 2022 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 883,461 0.2348
ARKG 4 Jan 2022 Buy SURF SURFACE ONCOLOGY INC 61,005 0.0059
ARKG 4 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 51,500 0.0141
ARKG 4 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 81,063 0.0279
ARKG 4 Jan 2022 Buy PSNL PERSONALIS INC 29,469 0.0077
ARKG 4 Jan 2022 Buy ONEM 1LIFE HEALTHCARE INC 176,830 0.0602
ARKG 4 Jan 2022 Buy NVTA INVITAE CORP 80,000 0.0220
ARKG 4 Jan 2022 Buy NTLA INTELLIA THERAPEUTICS INC 22,910 0.0484
ARKG 4 Jan 2022 Buy MASS 908 DEVICES INC 102,840 0.0499
ARKG 4 Jan 2022 Buy CGEN COMPUGEN LTD 23,216 0.0020
ARKG 4 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 62,542 0.0117
ARKG 3 Jan 2022 Buy TDOC TELADOC HEALTH INC 19,500 0.0368
ARKG 3 Jan 2022 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 71,144 0.0195
ARKG 3 Jan 2022 Buy SURF SURFACE ONCOLOGY INC 8,900 0.0009
ARKG 3 Jan 2022 Buy SGFY SIGNIFY HEALTH INC 13,200 0.0039
ARKG 3 Jan 2022 Buy RXRX RECURSION PHARMACEUTICALS INC 35,900 0.0129
ARKG 3 Jan 2022 Buy PSNL PERSONALIS INC 39,299 0.0111
ARKG 3 Jan 2022 Buy ONEM 1LIFE HEALTHCARE INC 29,100 0.0105
ARKG 3 Jan 2022 Buy MASS 908 DEVICES INC 24,812 0.0127
ARKG 3 Jan 2022 Buy CGEN COMPUGEN LTD 14,413 0.0012
ARKG 3 Jan 2022 Buy BNR BURNING ROCK BIOTECH LTD 59,175 0.0118
ARKG 3 Jan 2022 Buy BEAM BEAM THERAPEUTICS INC 14,400 0.0229
ARKG 31 Dec 2021 Buy SURF SURFACE ONCOLOGY INC 83,917 0.0078
ARKG 31 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 23,900 0.0067
ARKG 31 Dec 2021 Buy CGEN COMPUGEN LTD 36,600 0.0031
ARKG 30 Dec 2021 Sell VRTX VERTEX PHARMACEUTICALS INC 21,551 0.0956
ARKG 30 Dec 2021 Buy SURF SURFACE ONCOLOGY INC 23,723 0.0023
ARKG 30 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 100 0.0000
ARKG 30 Dec 2021 Buy PSNL PERSONALIS INC 1,100 0.0003
ARKG 30 Dec 2021 Buy MASS 908 DEVICES INC 100 0.0000
ARKG 30 Dec 2021 Buy CRSP CRISPR THERAPEUTICS AG 10,000 0.0158
ARKG 30 Dec 2021 Buy CGEN COMPUGEN LTD 66,398 0.0058
ARKG 30 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 5,200 0.0084
ARKG 30 Dec 2021 Sell ALLO ALLOGENE THERAPEUTICS INC 164 0.0000
ARKG 29 Dec 2021 Sell VRTX VERTEX PHARMACEUTICALS INC 24,007 0.1036
ARKG 29 Dec 2021 Sell TXG 10X GENOMICS INC 33,989 0.0957
ARKG 29 Dec 2021 Buy TDOC TELADOC HEALTH INC 22,500 0.0397
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.